company background image
VYGR logo

Voyager Therapeutics NasdaqGS:VYGR Stock Report

Last Price

US$8.51

Market Cap

US$478.7m

7D

1.1%

1Y

-34.4%

Updated

14 Jun, 2024

Data

Company Financials +

Voyager Therapeutics, Inc.

NasdaqGS:VYGR Stock Report

Market Cap: US$478.7m

Voyager Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Voyager Therapeutics
Historical stock prices
Current Share PriceUS$8.51
52 Week HighUS$14.07
52 Week LowUS$6.06
Beta1.04
1 Month Change-0.70%
3 Month Change-8.30%
1 Year Change-34.39%
3 Year Change89.53%
5 Year Change-69.31%
Change since IPO-52.06%

Recent News & Updates

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 05

Recent updates

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 05

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Mar 15
There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Mar 08

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Mar 04
What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Jan 04
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Oct 04

Voyager Therapeutics hires new finance chief

Sep 07

Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02

Aug 04

Looking Back In On Voyager Therapeutics

Jun 08

Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

May 12
Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

Voyager Does A Reboot After First Generation Failures

Mar 25

Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky

Feb 07
Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky

Voyager Therapeutics: Another Year, Another Deal

Nov 21

Some Analysts Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

Aug 11
Some Analysts Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

Newsflash: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Analysts Have Been Trimming Their Revenue Forecasts

Jul 18
Newsflash: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Analysts Have Been Trimming Their Revenue Forecasts

Shareholder Returns

VYGRUS BiotechsUS Market
7D1.1%0.2%1.2%
1Y-34.4%7.4%20.5%

Return vs Industry: VYGR underperformed the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: VYGR underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is VYGR's price volatile compared to industry and market?
VYGR volatility
VYGR Average Weekly Movement8.3%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: VYGR has not had significant price volatility in the past 3 months.

Volatility Over Time: VYGR's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013162Al Sandrockwww.voyagertherapeutics.com

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer’s disease and is in preclinical trial.

Voyager Therapeutics, Inc. Fundamentals Summary

How do Voyager Therapeutics's earnings and revenue compare to its market cap?
VYGR fundamental statistics
Market capUS$478.66m
Earnings (TTM)-US$3.04m
Revenue (TTM)US$119.04m

3.9x

P/S Ratio

-152.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VYGR income statement (TTM)
RevenueUS$119.04m
Cost of RevenueUS$100.70m
Gross ProfitUS$18.35m
Other ExpensesUS$21.39m
Earnings-US$3.04m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.056
Gross Margin15.41%
Net Profit Margin-2.56%
Debt/Equity Ratio0%

How did VYGR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.